Recent Updates
Recently added Catalysts
PLX Positive Sentiment

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Wednesday, August 12, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Protalix BioTherapeutics reported a strong financial performance for the second quarter of 2026, with revenues from goods sold reaching $19.8 million, an increase of $4.4 million compared to the same period in 2025. The total revenue for the year to date is $53.6 million, indicating robust growth largely attributed to the sales of Elfabrio®.

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenues increased to $19.8 million in Q2 2026.
  • Total revenue for the year reached $53.6 million.
  • Sales growth driven primarily by Elfabrio®.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+52%
120-day peak, hindsight
Typical move
10.5%
average across 3 past catalysts
Lead asset
PRX-115
Phase 2 · Gout

Full Press Release Details

Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio ® Total revenue climbed to $53.6 million, year to date,

Frequently Asked Questions

What were Protalix's revenues for Q2 2026?

Protalix reported revenues of $19.8 million for the second quarter of 2026.

How much did total revenue increase year to date?

Total revenue for the year to date reached $53.6 million.

What product primarily drove revenue growth?

Sales of Elfabrio® primarily drove the revenue growth.

When is the conference call for Q2 results?

The conference call is scheduled for today at 8:00 a.m. EDT.

ShareAdd on Google
Tags: PLX Viatris Investor Conferences Healthcare Protalix Elfabrio Q2 2026 financial results biopharma
Last updated: Aug 12, 2026

Biotech snapshot

Cash runway
$27M liquidity · $0M/mo burn
Low dilution risk
Lead asset
PRX-115Phase 2
Gout →

Catalyst track record

+52%
best trade around PLX's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for PLX.

See every catalyst's timing & PoA →